Company Overview of Enumeral Biomedical Holdings, Inc.
Enumeral Biomedical Holdings, Inc. engages in discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. It is developing antibodies against a number of classes of immunomodulatory proteins expressed on the surface of cells of the immune system for the treatment of cancer, autoimmune, and inflammatory diseases. Enumeral Biomedical Holdings, Inc. has a collaboration agreement with Merck Sharp & Dohme Corp.; and research contract with the National Cancer Institute. Enumeral Biomedical Holdings, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.
200 CambridgePark Drive
Cambridge, MA 02140
Founded in 2009
Key Executives for Enumeral Biomedical Holdings, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $174.6K
Co-Founder and Executive Chairman
Total Annual Compensation: $167.4K
Chief Accounting Officer, Vice President of Finance and Treasurer
Total Annual Compensation: $85.4K
Vice President of Business Development
Total Annual Compensation: $171.3K
Compensation as of Fiscal Year 2014.
Enumeral Biomedical Holdings, Inc. Key Developments
Enumeral Biomedical Holdings, Inc. Announces Recent Progress in its PD-1 Antibody Program
Jul 14 15
Enumeral Biomedical Holdings, Inc. announced recent progress in its PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the company's R&D pipeline, including its TIM-3 antibody program. Enumeral has identified antibodies that appear to bind to PD-1 in a manner different from that of currently marketed anti-PD1 antibodies, while retaining activity in cell-based assays. The company has isolated more than 300 sequences of PD-1 binding antibodies from primary B cells in its PD-1 program. The company's bioinformatics analysis of sequences indicates that these antibodies are diverse, falling into 26 distinct clades, or families, that bind to PD-1. Enumeral has advanced six lead clones into pre-clinical characterization, four of which are undergoing humanization. The company anticipates that the humanization process will be completed by the end of the third quarter of 2015, which will enable initiation of cell line development for IND-enabling studies. In Enumeral's TIM-3 program, the company has isolated 180 screening hits and has sequenced 88 TIM-3 binding antibodies to date, and its screening efforts are ongoing. Enumeral's bioinformatics analysis indicates desirable diversity, with the antibodies falling into 17 unique clades that bind to TIM-3. Enumeral plans to apply its unique approach to cellular immune response profiling to further understand the utility of these different antibodies for modulation of different TILs. The company believes antibodies that block TIM-3 may potentiate anti-cancer immune responses, either as a monotherapy or in combination with other therapies, including other immune checkpoint-targeted drugs. The company currently anticipates nominating lead clones by the end of the third quarter 2015, and beginning the humanization process by the end of this year. Enumeral also noted that it is engaged in ongoing antibody screening in its LAG-3, OX40, and VISTA programs. Using human biopsy samples, the company intends to validate antibody blocking effects against these targets, and then assess potential monotherapy or combination therapy regimens using proprietary antibodies.
Enumeral Biomedical Holdings, Inc. Approves Amendment to the Certificate of Incorporation
Jun 19 15
Enumeral Biomedical Holdings, Inc. approved amendment to the certificate of incorporation at its AGM held on June 18, 2015.
Enumeral Biomedical Holdings, Inc. Announces Executive Appointments
Jun 4 15
Enumeral Biomedical Holdings, Inc. announced the expansion of its Scientific Advisory Board with the appointments of Giulio Draetta, M.D., Ph.D., and Kai Wucherpfennig, M.D., Ph.D., recognized leaders in the fields of tumor biology and cancer immunotherapy. Dr. Draetta is Director of the Institute for Applied Cancer Science at M.D. Anderson Cancer Center, where he is also Professor of Genomic Medicine and Professor of Molecular and Cellular Oncology. His research focuses on identifying disease-driving genes associated with melanoma, glioblastoma and pancreatic cancer. Prior to joining M.D. Anderson, Dr. Draetta was the Chief Research Business Development Officer and Deputy Director of the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute. He previously served as Merck Research Laboratories’ Vice President and Worldwide Basic Franchise Head of Oncology. Dr. Draetta is a co-founder of Karyopharm, which develops inhibitors of nuclear transport targets for the treatment of cancer and other diseases. He also was the co-founder and Head of Research of Mitotix (acquired by GPC Biotech), where he established programs in cancer, inflammation and infectious diseases. Dr. Wucherpfennig, M.D., Ph.D., is Professor and Co-chair of the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School. His work focuses on the discovery of genes that control the activity of cytotoxic T cells in the tumor microenvironment with in vivo models and using these insights for the development of cancer immunotherapies. Dr. Wucherpfennig election as a Fellow in the American Society for the Advancement of Science, his election as a member of the Henry Kunkel Society at Rockefeller University, and his election as a member of the American Society for Clinical Investigation.
Similar Private Companies By Industry
Recent Private Companies Transactions